MRNS Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into MRNS

Also see:
MRNS stock yearly return 2014
MRNS stock yearly return 2015
MRNS stock yearly return 2016
MRNS stock yearly return 2017
MRNS stock yearly return 2018
MRNS stock yearly return 2019
MRNS stock yearly return 2020
MRNS stock yearly return 2021
MRNS stock yearly return 2022
MRNS YTD return
Compare MRNS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 08/01/2014
End date: 03/23/2023
Start price/share: $32.00
End price/share: $6.18
Dividends collected/share: $0.00
Total return: -80.69%
MRNS Average Annual Return: -17.32%
Starting investment: $10,000.00
Ending investment: $1,931.07
Years: 8.65

MRNS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential. The MRNS average annual return since 2014 is shown above.

The Average Annual Return on the MRNS average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether MRNS average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the MRNS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree MRNS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Marinus Pharmaceuticals (MRNS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

MRSN Average Annual Return
MRTX Average Annual Return
MRVI Average Annual Return
MTEM Average Annual Return
MXCT Average Annual Return
MYGN Average Annual Return
MYMD Average Annual Return
NAOV Average Annual Return
NARI Average Annual Return
NATR Average Annual Return
More Healthcare companies »


MRNS Average Annual Return 10 Years | | Copyright © 2021 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.